Matches in SemOpenAlex for { <https://semopenalex.org/work/W2918786853> ?p ?o ?g. }
- W2918786853 endingPage "227" @default.
- W2918786853 startingPage "217" @default.
- W2918786853 abstract "Purpose: To investigate the link between treatment with CTLA-4 and PD-1 checkpoint blockade inhibitors and the development of noninfectious uveitis.Methods: A survey was distributed to uveitis specialists to identify patients who developed uveitis while receiving either PD-1 inhibitors pembrolizumab and nivolumab; PD-L1 inhibitors atezolizumab, avelumab, and durvalumab; or the CTLA-4 inhibitor ipilimumab.Results: Fifteen patients from seven institutions were identified. The most common cancer diagnosis (13/15) was malignant melanoma. Fourteen patients had a new uveitis diagnosis following checkpoint blockade administration (six anterior uveitis, six panuveitis, one posterior uveitis, one anterior/intermediate combined); one patient developed optic neuritis. Uveitis was diagnosed within 6 months after drug initiation for 11/12 patients (median 63 days). Corticosteroid treatment was effective for most patients, although two patients had permanent loss of vision.Conclusions: Patients on checkpoint inhibitor therapy should be educated to seek care if they develop ocular symptoms, and prompt referral to specialists should be incorporated into oncology protocols." @default.
- W2918786853 created "2019-03-11" @default.
- W2918786853 creator A5015412172 @default.
- W2918786853 creator A5022167501 @default.
- W2918786853 creator A5026242706 @default.
- W2918786853 creator A5026780957 @default.
- W2918786853 creator A5046597133 @default.
- W2918786853 creator A5049381472 @default.
- W2918786853 creator A5055737789 @default.
- W2918786853 creator A5066556137 @default.
- W2918786853 creator A5069289540 @default.
- W2918786853 creator A5069631484 @default.
- W2918786853 creator A5081736910 @default.
- W2918786853 date "2019-03-01" @default.
- W2918786853 modified "2023-10-13" @default.
- W2918786853 title "Uveitis in Patients Treated with CTLA-4 and PD-1 Checkpoint Blockade Inhibition" @default.
- W2918786853 cites W1498187417 @default.
- W2918786853 cites W1575205563 @default.
- W2918786853 cites W1809627231 @default.
- W2918786853 cites W1984030154 @default.
- W2918786853 cites W1987030266 @default.
- W2918786853 cites W1990675339 @default.
- W2918786853 cites W1996262957 @default.
- W2918786853 cites W2007205635 @default.
- W2918786853 cites W2052078062 @default.
- W2918786853 cites W2068861451 @default.
- W2918786853 cites W2097995306 @default.
- W2918786853 cites W2101653483 @default.
- W2918786853 cites W2118982164 @default.
- W2918786853 cites W2122228353 @default.
- W2918786853 cites W2128035403 @default.
- W2918786853 cites W2143163879 @default.
- W2918786853 cites W2152897456 @default.
- W2918786853 cites W2160834915 @default.
- W2918786853 cites W2166662937 @default.
- W2918786853 cites W2169351454 @default.
- W2918786853 cites W2201460159 @default.
- W2918786853 cites W2265285917 @default.
- W2918786853 cites W2266680384 @default.
- W2918786853 cites W2301262881 @default.
- W2918786853 cites W2310090962 @default.
- W2918786853 cites W2320964824 @default.
- W2918786853 cites W2336823955 @default.
- W2918786853 cites W2338494814 @default.
- W2918786853 cites W2486996368 @default.
- W2918786853 cites W2487303921 @default.
- W2918786853 cites W2510997244 @default.
- W2918786853 cites W2519982410 @default.
- W2918786853 cites W2521389196 @default.
- W2918786853 cites W2521587286 @default.
- W2918786853 cites W2526699566 @default.
- W2918786853 cites W2563290770 @default.
- W2918786853 cites W2587959153 @default.
- W2918786853 cites W2598424499 @default.
- W2918786853 cites W2600712587 @default.
- W2918786853 cites W2600779842 @default.
- W2918786853 cites W2604909450 @default.
- W2918786853 cites W2616423891 @default.
- W2918786853 cites W2624988838 @default.
- W2918786853 cites W2651461248 @default.
- W2918786853 cites W2724136428 @default.
- W2918786853 cites W2736371654 @default.
- W2918786853 cites W2745214315 @default.
- W2918786853 cites W2759283067 @default.
- W2918786853 cites W2772873340 @default.
- W2918786853 cites W2791326819 @default.
- W2918786853 cites W2793148270 @default.
- W2918786853 cites W2803024933 @default.
- W2918786853 cites W2811286837 @default.
- W2918786853 cites W2918950605 @default.
- W2918786853 doi "https://doi.org/10.1080/09273948.2019.1577978" @default.
- W2918786853 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6832811" @default.
- W2918786853 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30821569" @default.
- W2918786853 hasPublicationYear "2019" @default.
- W2918786853 type Work @default.
- W2918786853 sameAs 2918786853 @default.
- W2918786853 citedByCount "51" @default.
- W2918786853 countsByYear W29187868532019 @default.
- W2918786853 countsByYear W29187868532020 @default.
- W2918786853 countsByYear W29187868532021 @default.
- W2918786853 countsByYear W29187868532022 @default.
- W2918786853 countsByYear W29187868532023 @default.
- W2918786853 crossrefType "journal-article" @default.
- W2918786853 hasAuthorship W2918786853A5015412172 @default.
- W2918786853 hasAuthorship W2918786853A5022167501 @default.
- W2918786853 hasAuthorship W2918786853A5026242706 @default.
- W2918786853 hasAuthorship W2918786853A5026780957 @default.
- W2918786853 hasAuthorship W2918786853A5046597133 @default.
- W2918786853 hasAuthorship W2918786853A5049381472 @default.
- W2918786853 hasAuthorship W2918786853A5055737789 @default.
- W2918786853 hasAuthorship W2918786853A5066556137 @default.
- W2918786853 hasAuthorship W2918786853A5069289540 @default.
- W2918786853 hasAuthorship W2918786853A5069631484 @default.
- W2918786853 hasAuthorship W2918786853A5081736910 @default.
- W2918786853 hasBestOaLocation W29187868532 @default.
- W2918786853 hasConcept C118487528 @default.
- W2918786853 hasConcept C121332964 @default.
- W2918786853 hasConcept C121608353 @default.